89640-03-9 Usage
General Description
Ethyl 5-chloro-4-nitrothiophene-2-carboxylate is a chemical compound with a molecular formula of C9H6ClNO4S. It is a thiophene derivative that contains a nitro group, a chloro group, and an ester functional group. Ethyl 5-chloro-4-nitrothiophene-2-carboxylate is commonly used in organic synthesis as a building block for the preparation of various pharmaceuticals, agrochemicals, and other fine chemicals. It is also used as an intermediate in the production of other complex organic molecules. Ethyl 5-chloro-4-nitrothiophene-2-carboxylate is known for its versatile reactivity and ability to undergo various chemical reactions, making it a valuable compound in the field of organic chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 89640-03-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,9,6,4 and 0 respectively; the second part has 2 digits, 0 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 89640-03:
(7*8)+(6*9)+(5*6)+(4*4)+(3*0)+(2*0)+(1*3)=159
159 % 10 = 9
So 89640-03-9 is a valid CAS Registry Number.
89640-03-9Relevant articles and documents
Design, synthesis, and biological evaluation of novel 3-(thiophen-2-ylthio)pyridine derivatives as potential multitarget anticancer agents
Xi, Jian-Jun,He, Ruo-Yu,Zhang, Jian-Kang,Cai, Zhao-Bin,Zhuang, Rang-Xiao,Zhao, Yan-Mei,Shao, Yi-Dan,Pan, Xu-Wang,Shi, Ting-Ting,Dong, Zuo-Jun,Liu, Shou-Rong,Kong, Li-Min
, (2019/08/01)
A series of novel 3-(thiophen-2-ylthio)pyridine derivatives as insulin-like growth factor 1 receptor (IGF-1R) inhibitors was?designed and synthesized. IGF-1R kinase inhibitory activities and cytotoxicities against HepG2 and WSU-DLCL2 cell lines were teste
ANTI-VIRAL COMPOUNDS
-
Page/Page column 126, (2008/12/08)
Compounds effective in inhibiting replication of Hepatitis C virus ( HCV ) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, coformulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.